China's drug regulator accepts Novo Nordisk's filing for the Wegovy pill

Novo Nordisk said on Thursday, August 27, that China's drug regulator accepted its application to sell the oral version of its GLP-1 weight-loss drug Wegovy, a step that starts the formal review in the world's second-largest pharmaceutical market ^[1].

Acceptance is not approval. It means the regulator agreed the filing is complete enough to review. Novo has not said when a decision might come. "We respect the regulatory review process and therefore we are not able to offer information on potential approval timelines," the Danish drugmaker said in a statement ^[1].

A crowded race in China

Novo is playing catch-up to Eli Lilly in China ^[1]. Lilly said in March that it had submitted a marketing application for its once-daily pill orforglipron to Chinese regulators at the end of 2025, and a Lilly executive has told Reuters the drug could launch in China as soon as this year ^[1].

The injectable market there is already contested. Novo, Lilly, Pfizer and local firm Innovent Biologics are competing for share with once-weekly GLP-1 weight-loss injections ^[1]. China's National Health Commission has said the share of people who are overweight or obese could exceed 65% by 2030 ^[1].

The commercial stakes are large but still early. Sales of GLP-1 therapies for weight management in China could reach 30 billion yuan, about $4.46 billion, within the next five to seven years, up from an estimated 3 billion to 4 billion yuan today, according to Yang Huang, J.P. Morgan's head of China healthcare research ^[1]. That works out to roughly a sevenfold to tenfold increase over the current market.

Where the Wegovy pill already stands

The oral form of semaglutide sold as Wegovy has already cleared regulators in the United States and Britain ^[1]. Novo launched the tablet in the US market on January 5 and has since launched it in the United Arab Emirates and the United Kingdom ^[2].

Lilly's oral drug followed in the US, securing approval in April for orforglipron, which is also in the GLP-1 class of medicines that mimic a gut hormone to curb appetite and regulate blood sugar in people with diabetes ^[1].

Both companies have said they believe weight-loss pills could draw in patients who are reluctant to use injections ^[1].

Why it matters for patients

For people in the United States, this filing does not change what is on pharmacy shelves here. The Wegovy tablet is already approved and launched in the US ^[1][2], and this step concerns a separate national regulator with its own timeline and its own decision.

The indirect effects are worth watching, though. Companies that win approval in large markets usually scale up manufacturing and commercial operations to match. Pills are made and shipped differently than injections that need refrigeration and pens, so oral demand overseas draws on a different production base than the injector supply that caused US shortages in past years. Whether a China launch would affect US supply or pricing has not been reported.

Competition is the other thread. Two oral GLP-1 medicines from rival companies are now moving through the same markets at roughly the same time ^[1]. In the US, that competition has already produced dueling launches within months of each other. What that eventually means for US list prices, insurance coverage or cash-pay programs is not established by this announcement.

It is also a reminder of how differently these drugs are regulated country by country. Approval in the US or the UK does not carry over. Each regulator reviews its own dossier, and acceptance of a filing is only the opening step.

What happens next

China's National Medical Products Administration now reviews the application. No target decision date has been disclosed ^[1]. Lilly's competing oral drug application, submitted at the end of 2025, is further along, and the company has suggested a Chinese launch could come as early as this year ^[1].